Alvotech and Fuji Pharma (Tokyo Stock Exchange: 4554) today announce that the two companies are entering into an exclusive partnership for the commercialization by Fuji Pharma of Alvotech’s biosimilar portfolio in Japan. Under the partnership, Alvotech will be responsible for development and supply of multiple high value biosimilar assets from its current product pipeline, while Fuji Pharma will be responsible for registration and commercialization of these assets in Japan. Alvotech’s bio...